The antibody response in HIV-1-infected donorsRichardson, Simone I.a,b; Moore, Penny L.a,b,cCurrent Opinion in HIV and AIDS: July 2019 - Volume 14 - Issue 4 - p 233–239 doi: 10.1097/COH.0000000000000559 BROAD NEUTRALISING AND NON-NEUTRALISING ANTIBODIES: Edited by Hugo Mouquet and Olivier Schwartz Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Although the goal of preventive HIV vaccine design is primarily the induction of broadly neutralizing antibodies (bNAbs), recent evidence suggests that a protective response will also benefit from Fc effector functions. Here, we provide an update on the antibody response to HIV infection, including both Fab and Fc-mediated antibody responses. We also highlight recent studies showing the interplay between these functions, focusing primarily on studies published in the last year. Recent findings Identification and characterization of bNAb donors continues to provide insights into viral factors that are potentially translatable to vaccine design. Improved and more diverse measures of Fc effector function, and modulators thereof, are enabling a deeper understanding of their role in infection. New data providing mechanistic links between the innate and adaptive humoral immune responses are creating exciting opportunities for vaccine strategies, with the aim of eliciting a polyfunctional protective response. Summary New insights into the overall humoral response to HIV infection are defining diverse and synergistic mechanisms required for antibody protection from HIV through vaccination. aCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service bFaculty of Health Sciences, University of the Witwatersrand, Johannesburg cCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa Correspondence to Penny L. Moore, Centre for HIV and STIs, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa. Tel: +27 11 386 6331; fax: +27 11 386 6333; e-mail: firstname.lastname@example.org Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.